NASDAQ · Biotechnology · USD

eXoZymes, Inc. (EXOZ) Stock Analysis

eXoZymes, Inc. (EXOZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EXOZ

$3.92

−$0.20 (−4.85%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EXOZ with… →

EXOZ Key Statistics

As of Oct 21, 2026

Trading

Open: $4.15
Previous Close: $4.12
Day's Range: 3.92–4.70
52-Week Range: 3.71–18.40
Volume: 19.96K

Valuation

Market Cap: $36.47M
P/E Ratio: unprofitable
EPS (ttm): −1.19

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$9.16M
Shares Outstanding: 9.30M
1-Year Return: −68.85%

Dividend and dates

Avg Volume: 7.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EXOZ closed at $3.92, −68.85% over 1 year.

eXoZymes, Inc. (EXOZ) has a market capitalization of $36.47M.

In fiscal 2025, EXOZ reported revenue of $0.00.

EXOZ Stock Return by Calendar Year

eXoZymes, Inc. (EXOZ) return since Nov 2024: what $10,000 became

1 year: $10,000 $3,115; −68.85%
Since Nov 2024: $10,000 $4,532; −54.68%

If you had invested $10,000 in eXoZymes, Inc. (EXOZ) at the close on November 13, 2024, the earliest close on record here, it would have been worth $4,532 at the close on October 21, 2026: −54.68% in total, −33.56% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+90.75%−33.94%−64.04%

2024*20252026*

Year	Return
2026 (partial year)	−64.04%
2025	−33.94%
2024 (partial year)	+90.75%

As of October 21, 2026.

EXOZ Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$9.16M	—
2024	$0.00	−$5.86M	—
2023	$0.00	−$2.04M	—
2022	$0.00	−$1.40M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$9.72M	−$9.16M	—
2024	$0.00	—	−$5.93M	−$5.86M	—
2023	$0.00	—	−$1.80M	−$2.04M	—
2022	$0.00	—	−$1.33M	−$1.40M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

eXoZymes, Inc. (EXOZ) is capitalised at $36.47M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 32 employees.

The most recent close on file for EXOZ is $3.92, dated October 21, 2026. That is −$0.20 (−4.85%) against the previous close. The 52-week range on file runs from $3.71 to $18.40. The latest close sits 5.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $9.16M. Earnings per share on a trailing basis come to −1.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −68.85%. The stored price history starts on November 13, 2024, and the total return since then is −54.68%. Annualized volatility over the trailing 1 year is 79.06%.

Growth & Income

The record shows no dividend for EXOZ.

2026 is still running; the total return is −64.04% year to date. The record holds one complete calendar year, 2025, which returned −33.94%.

Peer Comparison

eXoZymes, Inc. (EXOZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
eXoZymes, Inc.	EXOZ	$36.47M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. eXoZymes, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About eXoZymes, Inc.

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Visit website →